Gandhi Ajay, Quinoa Travis R, Geller Eric, Khandelwal Priyank, Agarwalla Pankaj K
Department of Neurological Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
Institute of Neurology, Livingston, New Jersey, USA.
Headache. 2025 Feb;65(2):373-376. doi: 10.1111/head.14884. Epub 2025 Jan 26.
A patient with persistent refractory headaches from aneurysmal subarachnoid hemorrhage was treated with monthly erenumab injections, a monoclonal antibody to the calcitonin gene-related peptide (CGRP) receptor. These injections decreased the frequency and severity of the patient's debilitating headaches from daily to once or twice per month with positive improvement in function and quality of life. To our knowledge, this is the first reported case in the literature of a patient with persistent post-subarachnoid hemorrhage headache that was successfully treated with an antibody against the CGRP receptor. This case report highlights the role of CGRP in post-subarachnoid hemorrhage headaches and the potential role for CGRP pathway-based therapies as an effective treatment.
一名患有动脉瘤性蛛网膜下腔出血所致持续性难治性头痛的患者接受了每月一次的erenumab注射治疗，erenumab是一种针对降钙素基因相关肽（CGRP）受体的单克隆抗体。这些注射使患者使人衰弱的头痛频率和严重程度从每天发作降至每月一到两次，功能和生活质量得到了积极改善。据我们所知，这是文献中首次报道的一例持续性蛛网膜下腔出血后头痛患者通过抗CGRP受体抗体成功治疗的病例。本病例报告强调了CGRP在蛛网膜下腔出血后头痛中的作用以及基于CGRP途径的疗法作为有效治疗方法的潜在作用。
